Anthony Nolan Research Institute and University College London Medical School, UK.
Immunology. 2012 Jan;135(1):27-39. doi: 10.1111/j.1365-2567.2011.03508.x.
Cytomegalovirus (CMV) infection and reactivation pose a serious threat for patients after haematopoietic stem cell transplantation. We have previously shown that CD8(+) T cells targeting different CMV epitopes correlate with protection at different threshold frequencies in those patients. To investigate if this may relate to a different quality of these cells here we analyse the T-cell receptor diversity of pp50 (245-253)/HLA-A0101 specific CD8(+) T cells with that of CD8(+) T cells targeting various pp65 peptides. The results from this pilot study show differences in the breadth of the T-cell receptor usage of the different cell populations. We observe for the first time that the T-cell receptor Vβ CDR3 spectratypes used by CMV pp50 (245-253)/HLA-A0101-specific CD8(+) T cells can reach higher numbers than those used by CD8(+) T cells targeting various pp65 peptides in our patient cohort. This merits further investigation into the effectiveness of the different CMV-specific T cells and their impact on immunosenescence, which is important to eventually define the most useful source of adoptive therapy and monitoring protocols for cytomegalovirus-specific immune responses.
巨细胞病毒 (CMV) 感染和再激活对造血干细胞移植后的患者构成严重威胁。我们之前已经表明,针对不同 CMV 表位的 CD8(+) T 细胞与这些患者中不同阈值频率的保护相关。为了研究这是否与这些细胞的不同质量有关,我们在这里分析了 pp50(245-253)/HLA-A0101 特异性 CD8(+) T 细胞的 T 细胞受体多样性与针对各种 pp65 肽的 CD8(+) T 细胞的 T 细胞受体多样性。这项初步研究的结果表明,不同细胞群体的 T 细胞受体使用的广度存在差异。我们首次观察到,CMV pp50(245-253)/HLA-A0101 特异性 CD8(+) T 细胞使用的 T 细胞受体 Vβ CDR3 谱型数量可以高于我们患者队列中针对各种 pp65 肽的 CD8(+) T 细胞使用的数量。这值得进一步研究不同的 CMV 特异性 T 细胞的有效性及其对免疫衰老的影响,这对于最终确定最有用的过继治疗来源和细胞免疫反应监测方案非常重要。